New cocktail of drugs takes on tough liver cancer

NCT ID NCT07052253

Recruiting now Disease control Sponsor: Akeso Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing a combination of two immunotherapy drugs (AK104 and AK112) plus a targeted pill (TT-00420) in 100 people with advanced hepatocellular carcinoma that cannot be treated with local therapies. The main goal is to see how many patients' tumors shrink. Participants must not have had prior systemic cancer treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AK104, AK112 (immunotherapy drugs) and TT-00420 (tinengotinib, a targeted pill)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced liver cancer who have not had prior systemic therapy.
What could go wrong: This is an early-phase trial with only 100 participants, so results may not apply to everyone. The combination may cause significant side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Union Hospital Tongji Medical College Huazhong University of Science And Technology
RECRUITING

Wuhan, China, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.